Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

ClinicalTrials.gov ID: NCT06029426

Public ClinicalTrials.gov record NCT06029426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA-335140 501).

Study identification

NCT ID
NCT06029426
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Enrollment
383 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 20, 2023 (Actual)
Primary completion
Dec 3, 2024 (Actual)
Completion
Jan 15, 2025 (Actual)
Last update posted
Nov 26, 2025

2023 – 2025

United States locations

U.S. sites
64
U.S. states
20
U.S. cities
59
Facility City State ZIP Site status
Neumora Investigator Site Huntsville Alabama 35801 —
Neumora Investigator Site Phoenix Arizona 85012 —
Neumora Investigator Site Bentonville Arkansas 72712 —
Neumora Investigator Site-1 Little Rock Arkansas 72211 —
Neumora Investigator Site Little Rock Arkansas 72211 —
Neumora Investigator Site Rogers Arkansas 72758 —
Neumora Investigator Site Bellflower California 90706 —
Neumora Investigator Site Garden Grove California 92845 —
Neumora Investigator Site Glendale California 91206 —
Neumora Investigator Site Imperial California 92251 —
Neumora Investigator Site Lafayette California 94549 —
Neumora Investigator Site Long Beach California 90807 —
Neumora Investigator Site Los Angeles California 90015 —
Neumora Investigator Site Oceanside California 92056 —
Neumora Investigator Site Orange California 92868 —
Neumora Investigator Site Riverside California 92506 —
Neumora Investigator Site San Jose California 95124 —
Neumora Investigator Site #1 Sherman Oaks California 91403 —
Neumora Investigator Site Sherman Oaks California 91403 —
Neumora Investigator Site Temecula California 92591 —
Neumora Investigator Site Torrance California 90504 —
Neumora Investigator Site Colorado Springs Colorado 80910 —
Neumora Investigator Site Gainesville Florida 32607 —
Neumora Investigator Site Hallandale Florida 33009 —
Neumora Investigator Site Jacksonville Florida 32256 —
Neumora Investigator Site Lauderhill Florida 33319 —
Neumora Investigator Site Maitland Florida 32751 —
Neumora Investigator Site Miami Florida 33122 —
Neumora Investigator Site Miami Florida 33125 —
Neumora Investigator Site Miami Florida 33183 —
Neumora Investigator Site Miami Lakes Florida 33016 —
Neumora Investigator Site Orlando Florida 32801 —
Neumora Investigator Site Tampa Florida 33607 —
Neumora Investigator Site Marietta Georgia 30060 —
Neumora Investigator Site Chicago Illinois 60634 —
Neumora Investigator Site Evanston Illinois 60201 —
Neumora Investigator Site Warrenville Illinois 60555 —
Neumora Investigator Site Boston Massachusetts 02116 —
Neumora Investigator Site Methuen Massachusetts 01844 —
Neumora Investigator Site Watertown Massachusetts 02472 —
Neumora Investigator Site Bloomfield Hills Michigan 48302 —
Neumora Investigator Site Flowood Mississippi 39232 —
Neumora Investigator Site Saint Charles Missouri 63304 —
Neumora Investigator Site Las Vegas Nevada 89102 —
Neumora Investigator Site Brooklyn New York 11224 —
Neumora Investigator Site Cedarhurst New York 11516 —
Neumora Investigator Site New York New York 10036 —
Neumora Investigator Site Staten Island New York 10314 —
Neumora Investigator Site Cleveland Ohio 44106 —
Neumora Investigator Site Columbus Ohio 43210 —
Neumora Investigator Site Dayton Ohio 45417 —
Neumora Investigator Site Garfield Heights Ohio 44125 —
Neumora Investigator Site Allentown Pennsylvania 18104 —
Neumora Investigator Site Media Pennsylvania 19063 —
Neumora Investigator Site Plymouth Meeting Pennsylvania 19462 —
Neumora Investigator Site Memphis Tennessee 38119 —
Neumora Investigator Site Austin Texas 78737 —
Neumora Investigator Site Dallas Texas 75235 —
Neumora Investigator Site Houston Texas 77030 —
Neumora Investigator Site Houston Texas 77090 —
Neumora Investigator Site Wichita Falls Texas 76309 —
Neumora Investigator Site Charlottesville Virginia 22903 —
Neumora Investigator Site Bellevue Washington 98007 —
Neumora Investigator Site Everett Washington 98201 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06029426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 26, 2025 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06029426 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →